This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alcon (ALC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
by Zacks Equity Research
Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.
Alcon (ALC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Countdown to Alcon (ALC) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Philips (PHG) Extends Isala Partnership, Boosts Customer Base
by Zacks Equity Research
Philips (PHG) extends its partnership Isala hospital to optimize the latter's healthcare processes, expanding its customer base.
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.
Here's Why Alcon (ALC) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
by Zacks Equity Research
DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
by Nalak Das
We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.
Is Aveanna Healthcare (AVAH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Alcon (ALC) have performed compared to their sector so far this year.
Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio
by Zacks Equity Research
Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.
Are Options Traders Betting on a Big Move in Alcon (ALC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS
by Zacks Equity Research
Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.
Why Alcon (ALC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Philips (PHG) Boosts Precision Diagnosis With AI Platform
by Zacks Equity Research
Philips (PHG) boosts its Precision Diagnosis portfolio with an AI-powered ultrasound platform, strengthening its Diagnosis & Treatment segment.
Humana (HUM) Partners With UAB to Boost Care for MA Members
by Zacks Equity Research
Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.
Compelling Reasons to Hold on to Ensign Group (ENSG) Stock
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, an expanding healthcare portfolio and solid cash reserves.
Philips (PHG) Boosts Medical Imaging Footprint With New Move
by Zacks Equity Research
Philips (PHG) expands its international footprint with the wide availability of VeriSight Pro 3D to several Hong Kong hospitals, strengthening its Diagnosis & Treatment segment.
Reasons to Include Alcon (ALC) in Your Portfolio Right Now
by Zacks Equity Research
New product launches and strong solvency bode well for Alcon (ALC).
Philips (PHG) Strengthens Patient Monitoring Services in Spain
by Zacks Equity Research
Philips (PHG) announces the wide availability of its ambulatory cardiac monitoring service in Spain, boosting its patient monitoring solutions portfolio.